|
APAF1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.60270000002261E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.3037000000008E-05 |
| Normal-vs-Stage2 |
4.86269999999678E-06 |
| Normal-vs-Stage3 |
1.74340000003159E-06 |
| Normal-vs-Stage4 |
2.88049999996876E-06 |
| Stage1-vs-Stage2 |
1.047170E-01 |
| Stage1-vs-Stage3 |
9.698500E-02 |
| Stage1-vs-Stage4 |
7.843700E-02 |
| Stage2-vs-Stage3 |
6.897000E-01 |
| Stage2-vs-Stage4 |
9.310000E-01 |
| Stage3-vs-Stage4 |
6.141800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.22179999999473E-05 |
| Normal-vs-AfricanAmerican |
8.657900E-03 |
| Normal-vs-Asian |
2.282800E-03 |
| Caucasian-vs-AfricanAmerican |
8.869000E-01 |
| Caucasian-vs-Asian |
7.605800E-01 |
| AfricanAmerican-vs-Asian |
9.375200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.39079999999814E-05 |
| Normal-vs-Female |
1.76233999999997E-05 |
| Male-vs-Female |
9.969600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.724000E-03 |
| Normal-vs-Age(41-60Yrs) |
1.84932999999221E-05 |
| Normal-vs-Age(61-80Yrs) |
5.17959997115014E-09 |
| Normal-vs-Age(81-100Yrs) |
5.621600E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.916100E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.840100E-04 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.068200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.217800E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.725800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.951800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.888400E-02 |
| Classical-VS-Follicular |
1.57026999999532E-05 |
| Classical-VS-Other |
5.600800E-01 |
| Classical-VS-Normal |
1.136990E-03 |
| Tall-VS-Follicular |
3.158400E-01 |
| Tall-VS-Other |
7.731000E-01 |
| Tall-VS-Normal |
1.625940E-04 |
| Follicular-VS-Other |
4.230000E-01 |
| Follicular-VS-Normal |
2.76489999784246E-08 |
| Other-VS-Normal |
6.926200E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.90920000498718E-08 |
| Normal-vs-N1 |
3.77850000000679E-05 |
| N0-vs-N1 |
8.187200E-01 |
|
|
